Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients With Atrial Fibrillation
- 1 May 2013
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 6 (3), 451-460
- https://doi.org/10.1161/circheartfailure.112.000143
Abstract
We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin. The risk of a number of outcomes, including the composite of SSE or death (to take account of competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: (1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or LVSD (1.54; 5.27); each comparison P P =0.02); for SSE, major bleed, or death it was 0.85 (0.78–0.92; P <0.001). There was no heterogeneity of treatment effect across the 3 groups. Patients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00412984.Keywords
This publication has 21 references indexed in Scilit:
- Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort studyEuropean Heart Journal, 2012
- 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)Circulation, 2011
- Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyBMJ, 2011
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Improving Stroke Risk Stratification in Atrial FibrillationAmerican Journal Of Medicine, 2010
- Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial FibrillationStroke, 2008
- Independent predictors of stroke in patients with atrial fibrillationNeurology, 2007
- Validation of Clinical Classification Schemes for Predicting StrokeJama-Journal Of The American Medical Association, 2001
- Predictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at RiskAnnals of Internal Medicine, 1992
- Predictors of Thromboembolism in Atrial Fibrillation: II. Echocardiographic Features of Patients at RiskAnnals of Internal Medicine, 1992